In the Original Investigation titled “Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews,” published in the June issue of JAMA Cardiology,1 a conversion factor for a 1-mmol/L reduction of low-density lipoprotein (LDL) cholesterol in the Table and text was erroneously listed as 40.6 mg/dL instead of 38.7 mg/dL. In the first column of the Table, the third entry under Statins should have read, “Major vascular events per 38.7 mg/dL of LDL cholesterol level reduction.” In the Statins subsection of the Results section in the text, the last sentence of the Efficacy and Cardiovascular Benefits subsection should have read, “Treatment effects standardized per 38.7–mg/dL reduction in levels of low-density lipoprotein cholesterol were also reported by the Cholesterol Treatment Trialists’ Collaboration38 for all-cause mortality (RR, 0.91; 95% CI, 0.85-0.97) and major vascular events (RR, 0.75; 95% CI, 0.70-0.80).” This article was corrected online.
et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol
. 2016;1(3):341-349.PubMedGoogle ScholarCrossref